Significantly, increased DCBLD2 expression was linked to poorer overall survival in 8 types of cancer, inferior disease-free survival in 3 types of cancer, inferior disease-specific survival in 7 types of cancer, and inferior progression-free survival in 7 types of cancer (Cox p < 0.05, Fig. 3B). Here, DCBLD2 is linked to cancer.